CSI Market
Sign In | Register

Adamas Pharmaceuticals Inc (ADMS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ADMS Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Adamas Pharmaceuticals Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2021)
9 Months 		(Jun 30 2021) (Mar 31 2021) (Dec 31 2020) (Sep 30 2020)
Operating Activities
Income-44.44
Depreciation & amortization0.33
Amortization of Other Assets0.08
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase-1.10
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation5.52
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction10.51
Increase Decrease In Operating Lease Right of Use Assets1.17
Investment Income Net Amortization Of Discount And Premium-0.07
Income taxes0.00
Gain on Sale of Investments0.00
Accounts Receivable-1.98
Increase (Decrease) in Other Accounts Payable1.98
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-14.34
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets7.22
Other Working Capital0.00
Other Noncash Income0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.36
Discontinued operations0.00
Net Cash flow from Operating Activities-36.49
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities11.62
Payments to Acquire Marketable Securities-32.32
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired-1.33
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-22.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.66
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock67.18
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Convertible Promissory Notes And Related Warrants-
Proceeds From Issuance Of Employee Stock Purchase Plan-
Net Proceeds From Issuance Of Common Stock-
Proceeds From Paycheck Protection Program Loan-
Repayments Of Paycheck Protection Program Loan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities65.52
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-36.52
Total Cash Flow6.96
4 historic quarters locked

Sign in to unlock the full Adamas Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About ADMS Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.